MEXICO CITY, July 25,
2024 /PRNewswire/
-- Genomma Lab Internacional, S.A.B.
de C.V. (BMV: LABB) ("Genomma Lab"
or "the Company"), one of the leading pharmaceutical and personal
care product companies in Mexico
with an increasing international presence, today announced four
independent bolt-on brand acquisitions aligned with its strategy to
strengthen the Company's isotonic beverage, analgesic and gastro
category core brand portfolios.
Genomma Lab USA
Inc., the Company's U.S. subsidiary, acquired the Suero
Repone® and Suero Oral® brands
through two separate transactions, enabling the Company
to expand its points of sale and distributor base, and to
strengthen Suerox®'s footprint within the US
market. Notably, Genomma owns the "suero" concept within the US
Hispanic market through this acquisition.
Genomma Lab Argentina S.A. acquired the IBU
400® and Treg® brands through a
separate transaction. The acquisition enables Genomma to enter the
ibuprofen segment, the second largest analgesics category, further
strengthening the Company's position as the market leader in
paracetamol, the largest segment in analgesics, through
Tafirol®.
Treg® is one of the leading OTC
brands in the gastro category, particularly in Omeprazol.
"We successfully acquired four brands with strong
and well-established brand equity and consumer recognition in their
respective markets, as well as extensive distribution networks
which complement our current geographical footprint. We will
leverage our marketing and distribution capabilities while
enhancing our presence in the Isotonic Beverage, Analgesics and
Gastro categories. We are excited to add these strong, well-known
names to our core portfolio," commented Marco Sparvieri, CEO of Genomma Lab.
"We made a total investment of US $25.6 million to acquire brands that recorded USD
$21.7 million in trailing twelve
months sales. Importantly, we leveraged our Argentina-domiciled cash, complemented with
local debt; exchanging Argentine pesos for valuable assets," added
Antonio Zamora Galland, CFO of
Genomma Lab.
About Genomma Lab Internacional
Genomma Lab Internacional, S.A.B. de C.V. is one
of the leading pharmaceutical and personal care products companies
in Mexico with an increasing
international presence. Genomma Lab develops, sells and markets a
broad range of premium branded products, many of which are leaders
in the categories in which they compete in terms of sales and
market share. Genomma Lab relies on the combination of a successful
new product development process, a consumer-oriented
marketing, a broad retail distribution network and a low-cost,
highly flexible operating model.
Genomma Lab's shares are listed on the Mexican
Stock Exchange under the ticker "LAB B" (Bloomberg: LABB:MM).
View original
content:https://www.prnewswire.com/news-releases/genomma-lab-announces-strategic-bolt-on-acquisition-of-four-brands-302207199.html
SOURCE Genomma Lab Internacional, S.A.B. de C.V.